| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:CDK14_PPP1CC |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: CDK14_PPP1CC | KinaseFusionDB ID: KFG1100 | FusionGDB2.0 ID: KFG1100 | Hgene | Tgene | Gene symbol | CDK14 | PPP1CC | Gene ID | 5218 | 5501 | |
| Gene name | cyclin dependent kinase 14 | protein phosphatase 1 catalytic subunit gamma | ||||||||||
| Synonyms | PFTAIRE1|PFTK1 | PP-1G|PP1C|PPP1G | ||||||||||
| Cytomap | 7q21.13 | 12q24.11 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | cyclin-dependent kinase 14PFTAIRE protein kinase 1cell division protein kinase 14serine/threonine-protein kinase PFTAIRE-1 | serine/threonine-protein phosphatase PP1-gamma catalytic subunitprotein phosphatase 1, catalytic subunit, gamma isozymeprotein phosphatase 1C catalytic subunitserine/threonine phosphatase 1 gamma | ||||||||||
| Modification date | 20240416 | 20240407 | ||||||||||
| UniProtAcc | O94921 | P36873 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000265741, ENST00000380050, ENST00000406263, ENST00000436577, ENST00000496279, | ENST00000335007, ENST00000340766, ENST00000546933, ENST00000550991, ENST00000551676, ENST00000551690, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CDK14 [Title/Abstract] AND PPP1CC [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CDK14(90477739)-PPP1CC(111171933), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CDK14 | GO:0000086 | G2/M transition of mitotic cell cycle | 20059949 |
| Hgene | CDK14 | GO:0060828 | regulation of canonical Wnt signaling pathway | 20059949 |
| Kinase Fusion gene breakpoints across CDK14 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across PPP1CC (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | BF891152 | CDK14 | chr7 | 90477739 | PPP1CC | chr12 | 111171933 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:90477739/:111171933) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CDK14 | PPP1CC |
| FUNCTION: Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by mediating the phosphorylation of LRP6 at 'Ser-1490', leading to the activation of the Wnt signaling pathway. Acts as a regulator of cell cycle progression and cell proliferation via its interaction with CCDN3. Phosphorylates RB1 in vitro, however the relevance of such result remains to be confirmed in vivo. May also play a role in meiosis, neuron differentiation and may indirectly act as a negative regulator of insulin-responsive glucose transport. {ECO:0000269|PubMed:16461467, ECO:0000269|PubMed:17517622, ECO:0000269|PubMed:19524571, ECO:0000269|PubMed:20059949}. | FUNCTION: Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase 1 (PP1) is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Dephosphorylates RPS6KB1. Involved in regulation of ionic conductances and long-term synaptic plasticity. May play an important role in dephosphorylating substrates such as the postsynaptic density-associated Ca(2+)/calmodulin dependent protein kinase II. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). {ECO:0000269|PubMed:17936702, ECO:0000269|PubMed:20516061, ECO:0000269|PubMed:21712997, ECO:0000269|PubMed:23396208}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CDK14_PPP1CC |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CDK14 | O94921 | human | LRP6 | O75581 | S1490 | AILNPPPsPAtERsH | |
| CDK14 | O94921 | human | CCNY | Q8ND76 | S73 | stIFLsksQtDVREK | |
| CDK14 | O94921 | human | CCNY | Q8ND76 | S71 | RAstIFLsksQtDVR | |
| CDK14 | O94921 | human | CCNY | Q8ND76 | S83 | DVREKRKsLFINHHP | |
| CDK14 | O94921 | human | PPP1R2 | P41236 | S87 | GDDEDACsDtEAtEA | IPP-2 |
| CDK14 | O94921 | human | CCNY | Q8ND76 | S295 | sFPLEPLsRERAHkL | |
| CDK14 | O94921 | human | CCNY | Q8ND76 | S288 | LAEANNLsFPLEPLs | |
| CDK14 | O94921 | human | TAGLN2 | P37802 | S83 | PVkkIQAstMAFkQM | CH |
| CDK14 | O94921 | human | CCNY | Q8ND76 | T67 | SDHPRAstIFLsksQ | |
| CDK14 | O94921 | human | TAGLN2 | P37802 | S163 | kENPRNFsDNQLQEG |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CDK14 | ID | Description | 0.00e+00 |
| CDK14 | GO:0071900 | regulation of protein serine/threonine kinase activity | 2.73e-02 |
| CDK14 | GO:0060070 | canonical Wnt signaling pathway | 2.73e-02 |
| CDK14 | GO:0045787 | positive regulation of cell cycle | 2.73e-02 |
| CDK14 | GO:1901998 | toxin transport | 2.73e-02 |
| CDK14 | GO:1904953 | Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation | 2.73e-02 |
| CDK14 | GO:0034392 | negative regulation of smooth muscle cell apoptotic process | 2.73e-02 |
| CDK14 | GO:0014029 | neural crest formation | 2.73e-02 |
| CDK14 | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 2.73e-02 |
| CDK14 | GO:0016055 | Wnt signaling pathway | 2.73e-02 |
| CDK14 | GO:0198738 | cell-cell signaling by wnt | 2.73e-02 |
| CDK14 | GO:1904948 | midbrain dopaminergic neuron differentiation | 2.73e-02 |
| CDK14 | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 2.73e-02 |
| CDK14 | GO:0071397 | cellular response to cholesterol | 2.80e-02 |
| CDK14 | GO:0036315 | cellular response to sterol | 3.18e-02 |
| CDK14 | GO:0070723 | response to cholesterol | 3.18e-02 |
| CDK14 | GO:0032367 | intracellular cholesterol transport | 3.18e-02 |
| CDK14 | GO:0034391 | regulation of smooth muscle cell apoptotic process | 3.18e-02 |
| CDK14 | GO:0034390 | smooth muscle cell apoptotic process | 3.18e-02 |
| CDK14 | GO:0032366 | intracellular sterol transport | 3.18e-02 |
| CDK14 | GO:0036314 | response to sterol | 3.18e-02 |
| CDK14 | GO:0071542 | dopaminergic neuron differentiation | 3.63e-02 |
| CDK14 | GO:0043666 | regulation of phosphoprotein phosphatase activity | 3.86e-02 |
| CDK14 | GO:0010656 | negative regulation of muscle cell apoptotic process | 3.86e-02 |
| CDK14 | GO:0032365 | intracellular lipid transport | 3.86e-02 |
| CDK14 | GO:0010921 | regulation of phosphatase activity | 4.43e-02 |
| CDK14 | GO:0001756 | somitogenesis | 4.54e-02 |
| CDK14 | GO:0005977 | glycogen metabolic process | 4.54e-02 |
| CDK14 | GO:0035304 | regulation of protein dephosphorylation | 4.54e-02 |
| CDK14 | GO:0044042 | glucan metabolic process | 4.54e-02 |
| CDK14 | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 4.54e-02 |
| CDK14 | GO:0010660 | regulation of muscle cell apoptotic process | 4.54e-02 |
| CDK14 | GO:0061053 | somite development | 4.54e-02 |
| CDK14 | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 4.54e-02 |
| CDK14 | GO:0006112 | energy reserve metabolic process | 4.54e-02 |
| CDK14 | GO:0010657 | muscle cell apoptotic process | 4.54e-02 |
| CDK14 | GO:0030901 | midbrain development | 4.54e-02 |
| CDK14 | GO:0014033 | neural crest cell differentiation | 4.54e-02 |
| CDK14 | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 4.54e-02 |
| CDK14 | GO:0005976 | polysaccharide metabolic process | 4.54e-02 |
| CDK14 | GO:0035282 | segmentation | 4.54e-02 |
| CDK14 | GO:0097306 | cellular response to alcohol | 4.54e-02 |
| CDK14 | GO:0035303 | regulation of dephosphorylation | 4.56e-02 |
| CDK14 | GO:0030301 | cholesterol transport | 5.37e-02 |
| CDK14 | GO:0000086 | G2/M transition of mitotic cell cycle | 5.53e-02 |
| CDK14 | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 5.53e-02 |
| CDK14 | GO:0015918 | sterol transport | 5.53e-02 |
| CDK14 | GO:0010508 | positive regulation of autophagy | 5.75e-02 |
| CDK14 | GO:0044839 | cell cycle G2/M phase transition | 5.82e-02 |
| CDK14 | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 6.31e-02 |
Top |
Related Drugs to CDK14_PPP1CC |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning CDK14-PPP1CC and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CDK14_PPP1CC |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |